| Literature DB >> 14984916 |
Peter van der Meer1, Adriaan A Voors, Erik Lipsic, Wiek H van Gilst, Dirk J van Veldhuisen.
Abstract
Several studies showed that anaemia is commonly observed in patients with Chronic Heart Failure (CHF) and is associated with worsened symptoms and survival. When anaemia in these patients is treated with erythropoietin (EPO), a significant improvement in cardiac function and symptoms was observed. Although it was originally believed that EPO specifically acted on haematopoietical cells, recent evidence demonstrated several non-haematopoietical effects. Ischaemia/reperfusion experiments in rat heart and brain showed large infarct reduction when treated with EPO. Other effects of EPO are related to its pro-angiogenic effects on endothelial cells, which could be of potential value in patients with ischaemic heart disease. These preclinical findings suggest that EPO may have potential effects in cardiovascular disease beyond correction of haemoglobin levels.Entities:
Mesh：
Substances：
Year: 2004 PMID： 14984916 DOI： 10.1016/j.ehj.2003.11.017
Source DB: PubMed Journal: Eur Heart J ISSN： 0195-668X Impact factor: 29.983